Simplify Logo

Full-Time

Variant Scientist

Posted on 10/18/2024

Tempus

Tempus

1,001-5,000 employees

AI-driven healthcare data analysis platform

AI & Machine Learning
Biotechnology
Healthcare

Compensation Overview

$90k - $100kAnnually

+ Incentive Compensation + Restricted Stock Units

Mid

Remote in USA

Category
Genomics
Biology Lab & Research
Biology & Biotech
Requirements
  • MS or PhD degree in Cancer Genetics, Human Genetics, or Biological Sciences
  • Prior experience in a diagnostic laboratory, clinical report writing, and familiarity with human mutation databases, genome browsers, and HGVS nomenclature is preferred. Oncology experience strongly preferred
  • Must have utmost attention to detail, excellent communication, and writing skills
  • Ability to accurately follow formal documentation and protocols
  • Ability to work in both an individual and group setting. Must be flexible and able to adjust priorities according to workload or management needs.
Responsibilities
  • Accurately classify somatic and germline variants for liquid biopsy, panel tests, and whole exome NGS sequencing
  • Utilize a variety of in-house software tools to analyze clinical molecular data
  • Read and interpret scientific literature and curate relevant findings in a clear, concise, and precise manner
  • Summarize somatic and inherited genetic test results to generate high quality clinical reports
  • Perform critical quality control functions for molecular reports that complies with quality management programs and standard operating procedures
  • Support improvements for current assays and processes
  • Curate variants, genes, and diseases for scientific and clinical relevance
  • May train junior team members
  • Work either Tuesday-Saturday or Sunday-Thursday shift

Tempus focuses on enhancing patient outcomes through the use of data and artificial intelligence in the healthcare sector. The company offers a platform that analyzes medical data, helping physicians make better treatment decisions by providing insights from medical images and identifying care gaps. For pharmaceutical and biotech companies, Tempus aids in drug development by discovering new targets and assessing treatment effectiveness. Patients benefit from personalized therapy options identified through the platform. Tempus conducts significant research, particularly in cancer, and has developed tools like a pan-cancer organoid platform and a liquid biopsy assay for profiling circulating tumor DNA. The company generates revenue by charging healthcare providers and companies for access to its platform and insights.

Company Stage

Series G

Total Funding

$1.3B

Headquarters

Chicago, Illinois

Founded

2015

Growth & Insights
Headcount

6 month growth

4%

1 year growth

13%

2 year growth

35%
Simplify Jobs

Simplify's Take

What believers are saying

  • Tempus's IPO and significant revenue generation indicate strong financial health and growth potential.
  • Collaborations with industry giants like SoftBank and United Therapeutics can lead to groundbreaking advancements and increased market share.
  • The company's focus on personalized therapy and AI-driven insights can significantly improve patient outcomes, making it a rewarding place to work for those passionate about healthcare innovation.

What critics are saying

  • The lawsuit from Guardant Health over patent infringement could result in financial and reputational damage.
  • Operating in a highly competitive market with peers like Foundation Medicine and Guardant Health requires continuous innovation to maintain a competitive edge.

What makes Tempus unique

  • Tempus leverages AI to provide actionable insights from medical data, setting it apart from competitors who may not integrate AI as deeply into their platforms.
  • Their focus on personalized therapy options and extensive cancer research, including a pan-cancer organoid platform and liquid biopsy assay, distinguishes them in the healthcare tech space.
  • Tempus's collaboration with major firms like SoftBank and United Therapeutics highlights its strong industry partnerships and credibility.

Help us improve and share your feedback! Did you find this helpful?